Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the first patients were enrolled in Esprit, a global Phase 2 clinical ...

A first-in-class gene-regulating therapy cut seizures by up to 91% in children with Dravet syndrome in extension studies, ...

Globus Medical is rated a buy, driven by robust earnings growth, margin recovery, and strong management guidance following a ...

The neuromyelitis optica spectrum disorder market size in the 7MM is expected to show positive growth during the forecast period (2026--2036), mainly attributed to the increasing prevalence of NMOSD, ...

Haemophilia prevalence is estimated at one in 10,000 live births, affecting up to 465,000 individuals globally, according to data from the World Federation of Haemophilia.Inside the living room of a ...

The Foundation for Angelman Syndrome Therapeutics (FAST) has helped redefine the role of advocacy groups. Founded and led by ...

New Zealanders with cancer and rare disorders will benefit from faster, locally delivered genomic testing through a new ...

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoingCash of $41.0 million as ...

Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated ...

Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those st ...

The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of around 20% during the forecast period. This rapid expansion is primarily fueled by the rising prevalence of ...